Advice

Following a full submission

Candesartan (Amias) is accepted for use within NHS Scotland for the treatment of patients with heart failure and left ventricular systolic dysfunction (left ventricular ejection fraction = 40%) as add-on therapy to ACE inhibitors or in patients who are unable to tolerate ACE inhibitors. Treatment with candesartan reduces mortality and hospitalisation due to heart failure. Candesartan may be used as a second-line agent in patients with chronic heart failure and LVEF = 40% following treatment with an ACE inhibitor and diuretic and with or without a betablocker.

Download detailed advice41KB (PDF)

Download

Medicine details

Medicine name:
Candesartan cilexetil (Amias®)
SMC ID:
161/05
Indication:
Heart failure and left ventricular systolic dysfunction
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Cardiovascular system
Submission type
Full
Status
Accepted
Date advice published
09 May 2005